AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $20,108,000 | +41.7% | 376,000 | -6.0% | 0.56% | -6.2% |
| Q1 2020 | $14,192,000 | -50.5% | 400,000 | -33.3% | 0.60% | -45.8% |
| Q4 2019 | $28,650,000 | +121.1% | 600,000 | +50.0% | 1.11% | +112.9% |
| Q3 2019 | $12,960,000 | -56.7% | 400,000 | -33.3% | 0.52% | -57.1% |
| Q2 2019 | $29,928,000 | -26.0% | 600,000 | 0.0% | 1.21% | -26.7% |
| Q1 2019 | $40,464,000 | +46.3% | 600,000 | 0.0% | 1.65% | +61.3% |
| Q4 2018 | $27,666,000 | +19.6% | 600,000 | +100.0% | 1.02% | +70.3% |
| Q3 2018 | $23,136,000 | -31.3% | 300,000 | -25.0% | 0.60% | -16.0% |
| Q2 2018 | $33,693,000 | -25.1% | 400,000 | -27.3% | 0.72% | +27.4% |
| Q1 2018 | $44,979,000 | +31.1% | 550,000 | -8.3% | 0.56% | +8.9% |
| Q4 2017 | $34,302,000 | +14.2% | 600,000 | +33.3% | 0.52% | 0.0% |
| Q3 2017 | $30,038,000 | -27.0% | 450,000 | -43.8% | 0.52% | -28.1% |
| Q2 2017 | $41,160,000 | -17.1% | 800,000 | -5.9% | 0.72% | -34.8% |
| Q1 2017 | $49,640,000 | -11.9% | 850,000 | -37.0% | 1.10% | -11.9% |
| Q4 2016 | $56,336,000 | +18.5% | 1,350,000 | +50.0% | 1.25% | +32.9% |
| Q3 2016 | $47,538,000 | +202.6% | 900,000 | +140.0% | 0.94% | +190.4% |
| Q2 2016 | $15,711,000 | -27.7% | 375,000 | -29.9% | 0.32% | -23.4% |
| Q1 2016 | $21,721,000 | -10.8% | 535,000 | +42.7% | 0.42% | -7.4% |
| Q4 2015 | $24,345,000 | +53.3% | 375,000 | +66.7% | 0.46% | +28.7% |
| Q3 2015 | $15,883,000 | -10.7% | 225,000 | +40.6% | 0.36% | -53.6% |
| Q2 2015 | $17,782,000 | +34.7% | 160,000 | +14.3% | 0.76% | +25.4% |
| Q1 2015 | $13,202,000 | +30.9% | 140,000 | +55.6% | 0.61% | +72.3% |
| Q4 2014 | $10,084,000 | -13.5% | 90,000 | -52.6% | 0.35% | -17.5% |
| Q3 2014 | $11,657,000 | +45.4% | 190,000 | +8.6% | 0.43% | +32.4% |
| Q2 2014 | $8,019,000 | +104.8% | 175,000 | +75.0% | 0.32% | +128.2% |
| Q1 2014 | $3,915,000 | +48.6% | 100,000 | -9.1% | 0.14% | +51.1% |
| Q4 2013 | $2,635,000 | +34.6% | 110,000 | +57.1% | 0.09% | +46.9% |
| Q3 2013 | $1,957,000 | – | 70,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |